High-dose therapy and autologous stem cell transplantation (ASCT) for poor-risk and relapsed non-Hodgkin's lymphoma (NHL): Long-term follow-up results and analysis of prognostic factors in 369 patients.

被引：0

作者：

Nademanee, A ^{[1
]}

Molina, A ^{[1
]}

Dagis, AC ^{[1
]}

O'Donnell, MR ^{[1
]}

Snyder, DS ^{[1
]}

Stein, A ^{[1
]}

Parker, PH ^{[1
]}

Wong, KK ^{[1
]}

Kashyap, A ^{[1
]}

Spielberger, RS ^{[1
]}

Fung, HC ^{[1
]}

Krishnan, A ^{[1
]}

Bhatia, R ^{[1
]}

Rodriquez, R ^{[1
]}

Vora, N ^{[1
]}

Sniecinski, I ^{[1
]}

Niland, JC ^{[1
]}

Forman, SJ ^{[1
]}

机构：

[1] City Hope Natl Med Ctr, Duarte, CA 91010 USA

来源：

BLOOD | 1999年 / 94卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

743

引用

页码：170A / 170A

页数：1

共 50 条

[31] Pulmonary mortality after high-dose oral busulfan and autologous stem cell transplant (ASCT) in patients with non-Hodgkin lymphoma (NHL).
Kalaycio, M
Pohlman, B
Rybicki, L
Sobecks, R
Kuczkowski, E
Andresen, S
Brown, S
Bolwell, B
BLOOD, 2005, 106 (11) : 501A - 502A
[32] High-Dose Chemotherapy (HDC) and Autologous Stem Cell Transplantation (ASCT) in patients with primary refractory aggressive Non-Hodgkin's lymphoma
Rodriguez, J
Caballero, MD
Solano, C
Lahuerta, JJ
Arranz, R
Sureda, A
Zuazu, J
Marin, J
García-Laraña, J
López-Guillermo, A
SanMiguel, J
Conde, E
BONE MARROW TRANSPLANTATION, 2001, 27 : S260 - S261
[33] Long term follow-up after autologous stem cell transplantation in refractory or relapsed Hodgkin lymphoma
Stamatoullas, A.
Lanic, H.
Contentin, N.
Nunes, K.
Picquenot, J. M.
Bastard, C.
Tilly, H.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 78 - 78
[34] High-Dose Therapy/Autologous Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Marginal Zone Non-Hodgkin Lymphoma
Li, Lanfang
Bierman, Philip
Vose, Julie
Loberiza, Fausto
Armitage, James O.
Bociek, R. Gregory
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (03): : 253 - 256
[35] High-dose chemotherapy with autologous stem cell transplantation in poor-risk aggressive non-Hodgkin lymphoma in first complete remission: an analysis of the prospective Tunisian study
Torjemane, L.
Ladeb, S.
Lakhal, A.
Abdelkefi, A.
Ben Abdelhadhim, A.
Ben Othman, T.
BONE MARROW TRANSPLANTATION, 2008, 41 : S256 - S256
[36] High dose therapy and autologous stem cell transplantation (HDT/ASCT) in Hodgkin's Lymphoma (HL). Outcome and prognostic factors
Angelopoulou, M. K.
Galanis, Z.
Vassilakopoulos, T. P.
Tsirkinidis, P.
Moschogiannis, M.
Dimitriadou, E.
Pappis, V.
Masouridis, S.
Chatzileonida, E.
Chasiotis, D.
Katsandris, K.
Kalotychou, V.
Boutsis, D.
Anargyrou, K.
Sachanas, S.
Dimopoulou, M. N.
Kokoris, S.
Kyrtsonis, M. C.
Siakantaris, M. P.
Rombos, I.
Pangalis, G. A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 79 - 80
[37] Autologous hematopoietic stem cell transplantation (ASCT) following high-dose therapy (HDT) for non-Hodgkin's lymphoma (NHL) in adults 60 years of age and older.
Gopal, A
Gooley, T
Golden, J
Maloney, D
Bensinger, W
Petersdorf, S
Appelbaum, F
Press, O
BLOOD, 1999, 94 (10) : 170A - 170A
[38] Second cancers after autologous hematopoietic stem cell transplantation (ASCT) for relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL)
Seshadri, Tara
Pintilie, Melania
Tsang, Richard
Kuruvilla, John
Zadeh, Sahar
Keating, Armand
Crump, Michael
BLOOD, 2007, 110 (11) : 499A - 499A
[39] A phase I/II trial of high-dose radioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous stem cell transplant (ASCT) in patients with poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL).
Nademanee, A
Molina, A
Forman, SJ
Kogut, N
Yamauchi, D
An, L
White, CA
Raubitschek, A
BLOOD, 2002, 100 (11) : 182A - 182A
[40] Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma
Laudi, N
Arora, M
Burns, LJ
Miller, JS
McGlave, PB
Barker, JN
Ramsay, NKC
Orchard, PJ
MacMillan, ML
Weisdoif, DJ
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 129 - 135

← 1 2 3 4 5 →